Pacific Edge Limited Ordinary Shares
PEB.NZXHealth Care
Pacific Edge Limited (NZX: PEB) is a New Zealand publicly listed, cancer diagnostic company specialising in the discovery and commercialisation of diagnostic and prognostic tests for better detection and management of cancer. Its Cxbladder suite of non-invasive, simple to use and accurate diagnostic tests provide actionable results, and better detection and management of urothelial cancer. The company is developing and commercialising its range of Cxbladder bladder cancer tests globally through its wholly owned central laboratories in New Zealand and the USA. The company’s products have been tested and validated in international multi-centre clinical studies.
Market Data
$0.280
+0.1%$328.2M
-7.4x
$-0.038
0.00%
+2.4%
Recent Announcements
SPH Notice - Harbour Asset Management Limited
Harbour Asset Management Limited changed substantial holding from 9.957% to 11.144%.
Retail Offer to Close 28 May 2026; Likely to be Scaled
Pacific Edge (NZX/ASX: PEB), a cancer diagnostics company, announced that its retail share offer closing on 28 May 2026 has received NZ$14.0 million in applications against a target of NZ$6 million, making scaling of applications likely. Eligible shareholders who applied will have their allocations scaled back proportionally based on their shareholdings as of 8 May 2026.
Advancing Medicare Coverage Goals; Cost Contained
Pacific Edge Limited reported FY26 audited financial results showing an operating revenue of NZ$11.5 million (down 47.4% from FY25) due to Medicare coverage loss, with a net loss of NZ$35.8 million; however, the company achieved a significant strategic milestone post-balance date with Novitas publishing a draft Local Coverage Determination (LCD DL40378) establishing Medicare coverage for its Cxbladder Triage and Triage Plus tests for microhematuria patients, with Triage Plus priced at US$1,328 offering improved unit economics and a pathway to profitability.
D&O Disclosures - Multiple
Pacific Edge Limited directors disclosed multiple share transactions: Bryan Raymond George Williams acquired 237,647 ordinary shares for $40,400 on 15-May-26 as part of a placement, and director Anatole Masfen sold 1,000,000 shares at $0.10 per share on 9-Sept-25 and purchased 10,579,950 shares at $0.17 per share on 13-Aug-25 through Opito Trust for $1,798,591.50.
SPH Notice - ANZ New Zealand Investments Limited
ANZ New Zealand Investments Limited changed substantial holding from 16.599% to 18.221%.
ASX - 2A - Capital Issue Placement
Pacific Edge Limited is applying for quotation of 149,384,548 ordinary fully paid shares issued on May 15, 2026, as part of a placement at NZD 0.17 per share for cash consideration. Following this quotation, the company will have 1,172,016,126 quoted ordinary shares on issue.
Capital Change Notice - Pacific Edge Placement
Pacific Edge Limited issued 149,384,548 ordinary shares at NZ$0.170 per share in a placement on 15 May 2026, representing 14.608% of the total class, with over 90% allocated to existing shareholders to maintain pro rata holdings.
Draft LCD Proposes Medicare Coverage for Triage and Triage
Pacific Edge announced that Medicare has published a draft Local Coverage Determination (LCD) proposing coverage for urine-based biomarkers in microhematuria evaluation, with explicit reimbursement guidance for the company's Cxbladder Triage and Triage Plus tests at US$1,328 per test. The company also noted it is conducting a retail share offering of up to NZ$6 million to eligible shareholders at NZ$0.17 per share, following a successful NZ$25.4 million placement.
Pacific Edge Opens NZ$6 Million Retail Offer
Pacific Edge Limited (NZX/ASX: PEB) has opened a NZ$6 million retail share offer to eligible New Zealand shareholders, allowing each to apply for up to NZ$50,000 of shares at NZ$0.17 per share—the same price as the recent NZ$25.4 million institutional placement. The offer runs until 28 May 2026, with proceeds intended to support operations, achieve Medicare re-coverage, and fund product development.
PEB – Trading to resume at Market Open
NZX has announced that trading in Pacific Edge Limited (PEB) equity shares will resume following a market announcement by the company on May 13, 2026.
Get real-time alerts for PEB
Receive AI-powered earnings summaries and instant notifications when Pacific Edge Limited Ordinary Shares releases results.
Register Free